FDA’s New ‘Super Office’ Attacks Pharmaceutical Quality Risks
This article was originally published in The Gold Sheet
Launched this month, CDER’s OPQ ‘Super Office’ blends the agency’s CMC review programs for new and generic drugs together, and focuses them on significant risks like the difficulty of release-testing modified-release drugs.
You may also be interested in...
The head of US FDA’s drug quality office comments on quality-related topics at the GRx-Biosims meeting; sheds more light on facility rating system plan.
In an unusual essay in the New England Journal of Medicine, CDER Director Janet Woodcock acknowledges that “the conservative approach did not provide the right conclusion regarding therapeutic equivalence in a timely manner.”
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.